The Motley Fool
20 Jul 2026, 23:24 UTC · 8w ago
Verdict
Headline takes no side. We score MNKD −0.60 across three claims — strongly bearish.
−0.60strongly bearish
More negative than 86% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
United Therapeutics' product Tresmi is positioned as a 'category killer' competitor to Tyvaso DPI, the inhaler MannKind collects royalties on.
More negative than 97% of claims this week
MannKind EVP Sanjay R. Singh forfeited 14,450 shares because the company failed to meet its 2023 compensation performance targets.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 84% of claims this week
MannKind EVP Sanjay R. Singh sold 46,795 shares of common stock on July 15, 2026.
More negative than 70% of claims this week
Which stocks this story touches
More negative than 86% of ticker scores this week
Executive forfeited shares due to performance shortfalls and faces a 'category killer' competitor product threatening royalties.
More positive than 59% of ticker scores this week
The company introduced a product described as a 'category killer' that negatively impacts a competitor's market position.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
1w ago
−11.1%
Price agrees with the score
$3.54 vs $3.98 close before publication (Jul 20) · not market-adjusted
MNKD chart →
